clinical trial · NCT06602024
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc.·phase3·completed·n = 40,817
Seasonal InfluenzamRNA-1010Fluarix®Influsplit® TetraFluarix TetraAlpharix® Tetra
brief summary
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
started
Sep 16, 2024
primary completion
Aug 21, 2025
completion
Aug 21, 2025
last updated
Sep 10, 2025
official title
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared With a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol